Multiplatform assay to classify formalin-fixed paraffin-embedded (FFPE) colorectal cancer (CRC) samples into molecular subtypes with mutational profiles
Elisa Fontana(Sarah Cannon Research Institute), Anguraj Sadanandam(Institute of Cancer Research), Sanna Hulkki-Wilson(Institute of Cancer Research), Irene Chong(Institute of Cancer Research), Ian Chau(Royal Marsden NHS Foundation Trust), Chanthirika Ragulan(Royal Marsden NHS Foundation Trust), Katherine Eason(University of Cambridge), Michael Hubank(Royal Marsden Hospital), Shuan Rao(Institute of Molecular Biotechnology), David Cunningham(Royal Marsden NHS Foundation Trust), Clare Peckitt(Royal Marsden NHS Foundation Trust), Gift Nyamundanda(Institute of Cancer Research), J. Oates(National Health Service), Maria Antonietta Bali(Royal Marsden NHS Foundation Trust), David Watkins, Francesco Sclafani(Royal Marsden NHS Foundation Trust), Nicola Valeri(Royal Marsden NHS Foundation Trust), Ruwaida Begum, Andrew Wotherspoon(Université Libre de Bruxelles), Naureen Starling(Royal Marsden NHS Foundation Trust)
Cited by 1
Related Papers
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury
|Nature Medicine|2005|3.7k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k